Amylyx Pharmaceuticals earnings were -$152.1M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest AMLX earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$43.4M, up 5.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, AMLX reported annual earnings of -$144.7M, with -52% growth. The next AMLX earnings date is Nov 5, 2026.
Amylyx Pharmaceuticals Earnings Reports & History FAQ
What were Amylyx Pharmaceuticals's earnings last quarter?
On AMLX's earnings call on Aug 6, 2026, Amylyx Pharmaceuticals (NASDAQ: AMLX) reported Q2 2026 earnings per share (EPS) of -$0.39, up 15.22% year over year. Total AMLX earnings for the quarter were -$43.42 million. In the same quarter last year, Amylyx Pharmaceuticals's earnings per share (EPS) was -$0.46.
The next AMLX earnings date is Nov 5, 2026. Add AMLX to your watchlist to be reminded of Amylyx Pharmaceuticals's next earnings date.
Is Amylyx Pharmaceuticals profitable or losing money?
As of the last Amylyx Pharmaceuticals earnings report, Amylyx Pharmaceuticals is currently losing money. Amylyx Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$152.09 million, a 18.93% decrease year over year.
What was AMLX's earnings growth in the past year?
As of Amylyx Pharmaceuticals's earnings date in Aug 6, 2026, Amylyx Pharmaceuticals's earnings has grown year over year. AMLX earnings in the past year totalled -$152.09 million.
What are Amylyx Pharmaceuticals's earnings expectations?
The current EPS estimate for Amylyx Pharmaceuticals's earnings report in Nov 5, 2026 is -$0.38.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.